ABBOTT LABORATORIES (NYSE:ABT) Files An 8-K Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
Item 2.03. Creation of a Direct Financial Obligation or an
Obligation Under an Off-Balance Sheet Arrangement of a Registrant
In connection with the settlement of the exchange offers, the
Company issued:
$473,770,000 aggregate principal amount of 2.000% Senior Notes
due 2018
$483,689,000 aggregate principal amount of 2.800% Senior Notes
due 2020
$818,429,000 aggregate principal amount of 3.25% Senior Notes due
2023
$490,690,000 aggregate principal amount of 3.875% Senior Notes
due 2025
$639,074,000 aggregate principal amount of 4.75% Senior Notes due
2043
(collectively, the New Notes). The offering of the New Notes
was registered under the Securities Act of 1933, as amended
(the Act) to a Registration Statement on FormS-4
(No.333-216141), which was filed with the Securities and
Exchange Commission (the SEC) on February21, 2017, as amended
on March7, 2017, and became effective on March20, 2017. The
terms of the New Notes are further described in the Companys
Prospectus dated March20, 2017, as filed with the SEC under
Rule 424(b)(3) of the Act on that date. The issuance of the New
Notes occurred on March22, 2017. The New Notes are unsecured
and unsubordinated obligations of the Company and rank equally
with all other unsecured and unsubordinated indebtedness of the
Company issued from time to time.
The New Notes were issued to an Indenture (the New Notes
Indenture), dated as of March10, 2015, between the Company and
U.S. Bank National Association, as trustee, as supplemented and
amended with respect to each series of the New Notes by the
terms thereof established, as applicable, to an officers
certificate.
The summaries of the New Notes Indenture and the New Notes do
not purport to be complete and are qualified in their entirety
by reference to the full text of such documents, which are
attached to this Current Report on Form8-K as Exhibits 4.1
through 4.6, and are incorporated by reference into this Item
2.03.
Item 8.01. Other Events
The information provided in the Introductory Note is
incorporated by reference into this Item 8.01.
Item 9.01Financial Statements and Exhibits
(d) Exhibits
|
Exhibit No. |
|
Exhibit |
|
4.1 |
Indenture, dated March10, 2015, between the Company and |
|
|
4.2 |
Formof 2.000% Notes due 2018 |
|
|
4.3 |
Formof 2.800% Notes due 2020 |
|
|
4.4 |
Formof 3.25% Notes due 2023 |
|
|
4.5 |
Formof 3.875% Notes due 2025 |
|
|
4.6 |
Formof 4.75% Notes due 2043 |
About ABBOTT LABORATORIES (NYSE:ABT)
Abbott Laboratories (Abbott) is engaged in the discovery, development, manufacture and sale of a line of healthcare products. The Company operates in four business segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products and Vascular Products. The Established Pharmaceutical Products segment includes the international sales of a line of branded generic pharmaceutical products. The Nutrition Products segment includes the sales of a line of adult and pediatric nutritional products. The Diagnostic Products includes the sales of diagnostic systems and tests for blood banks, hospitals, commercial laboratories and alternate-care testing sites. The Vascular Products includes the sales of coronary, endovascular, structural heart, vessel closure and other medical device products. ABBOTT LABORATORIES (NYSE:ABT) Recent Trading Information
ABBOTT LABORATORIES (NYSE:ABT) closed its last trading session down -0.06 at 44.74 with 5,567,081 shares trading hands.
